

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

H22

RRID:CVCL_H613

Type: Cell Line

Proper Citation

Ubigen Cat# YC-C053, RRID:CVCL_H613

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_H613

Proper Citation: Ubigen Cat# YC-C053, RRID:CVCL_H613

Description: Cell line H22 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Hepatocellular carcinoma of the mouse

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: H22

Synonyms: Hepatoma-22, Hepatoma 22

Cross References: CCRID:1101MOU-PUMC000309, CCRID:4201MOU-CCTCC00091, CCTCC:GDC0091, ChEMBL-Cells:ChEMBL3307751, ChEMBL-Targets:ChEMBL614998, CLS:305163, PubChem_Cell_line:CVCL_H613, Ubigen:YC-C053, Wikidata:Q54872017

ID: CVCL_H613

Vendor: Ubigen

Catalog Number: YC-C053

Record Creation Time: 20250130T071517+0000

Record Last Update: 20260830T001603+0000

Ratings and Alerts

No rating or validation information has been found for H22.

No alerts have been found for H22.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bi B, et al. (2026) MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma. *Molecular cancer therapeutics*, 25(5), 771.

Lin S, et al. (2026) Multi omics analysis reveals senescence associated genes in metabolic dysfunction associated steatohepatitis related liver cancer and their functional validation. *International journal of biological macromolecules*, 358, 151713.

Zhang X, et al. (2026) Tumor Cell-Derived Microparticles Induced by Methotrexate Reprogram Neutrophil Antitumor Response via Lysosomal ROS-Mediated Degranulation. *Molecular cancer research : MCR*, 24(4), 293.

Zhang X, et al. (2026) Synergistic mechanical and therapeutic modulation of engineered tumor cell-derived microparticles for enhanced cancer treatment. *Cell reports. Medicine*, 7(2), 102591.

Shen Z, et al. (2026) Plasmin promotes hepatocellular carcinoma invasion and metastasis via CXCR4-mediated activation of PI3K/AKT/mTOR signaling. *Oncogene*, 45(19), 1815.

Sun S, et al. (2026) Ammonia Detoxification Inhibits Liver Metastasis by Reshaping Hepatic Microenvironment. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(33), e21098.

Lin J, et al. (2026) Laparoscopic Delivery of a MnO₂-P-ICG Patch for Photodynamic Therapy and NK Cell-Driven Immunotherapy in Hepatocellular Carcinoma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(32), e24246.

Hao X, et al. (2026) Engineered CAR-NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(13), e21623.

Yu H, et al. (2025) UDP-GlcUA triggers PKR kinase activity to promote liquid-liquid phase separation of TOP2A and enhances radioimmunotherapy resistance. *Molecular cell*, 85(21), 3913.

Li B, et al. (2025) Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics. *Frontiers in immunology*, 16, 1539396.

Wang H, et al. (2025) Chebulinic acid shields Villin 1 from covalent attack to mitigate *Euphorbia fischeriana* enterotoxicity: A basis for safer anti-ascites therapy. *Journal of ethnopharmacology*, 353(Pt B), 120435.

Shan Y, et al. (2025) Hyaluronic Acid Hydrogel Implants for Sustained Release of Oxaliplatin and Resiquimod to Prevent Hepatocellular Carcinoma Recurrence Post-Radiofrequency Ablation. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(47), e09309.

Ruan YH, et al. (2025) Intracellular IL1 β in Peritumoral Monocytes Induces IL8 Production and Inhibits Mitophagy to Promote Stemness and Metastasis of Hepatocellular Carcinoma. *Cancer research*, 85(21), 4164.

Qiu L, et al. (2024) TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis. *EMBO molecular medicine*, 16(5), 1193.

Tang H, et al. (2024) Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy. *EBioMedicine*, 103, 105099.

Qiang N, et al. (2023) Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma. *International immunopharmacology*, 118, 110068.

Chang YW, et al. (2023) A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8 $^{+}$ T cells. *Cell reports. Medicine*, 4(8), 101154.

Hu B, et al. (2022) IFN γ Potentiates Anti-PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment. *Cancer discovery*, 12(7), 1718.

Yokoyama Y, et al. (2022) Sirpigenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems. *Molecular cancer therapeutics*, 21(10), 1561.

Cao M, et al. (2021) Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through α -adrenergic-activated CXCL5-CXCR2-Erk signaling cascades. *International journal of cancer*, 149(2), 460.